Barclays PLC Cuts Stock Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Barclays PLC lessened its holdings in COMPASS Pathways plc (NASDAQ:CMPS) by 1.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 410,476 shares of the company’s stock after selling 7,500 shares during the quarter. Barclays PLC’s holdings in COMPASS Pathways were worth $2,586,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Polar Asset Management Partners Inc. boosted its stake in shares of COMPASS Pathways by 83.3% in the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock valued at $3,576,000 after buying an additional 258,000 shares in the last quarter. Logos Global Management LP boosted its position in shares of COMPASS Pathways by 349.3% during the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock worth $7,001,000 after purchasing an additional 901,050 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of COMPASS Pathways by 1,518.4% during the 2nd quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock worth $1,593,000 after purchasing an additional 247,500 shares during the period. Sio Capital Management LLC increased its holdings in shares of COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after purchasing an additional 621,222 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of COMPASS Pathways in the third quarter valued at about $2,126,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CMPS shares. Maxim Group lowered their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada dropped their price objective on COMPASS Pathways from $23.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. HC Wainwright decreased their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $33.60.

COMPASS Pathways Trading Down 0.5 %

Shares of COMPASS Pathways stock opened at $4.03 on Wednesday. The business has a 50 day moving average price of $4.99 and a 200 day moving average price of $6.18. The company has a market capitalization of $275.74 million, a P/E ratio of -1.83 and a beta of 2.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1 year low of $3.86 and a 1 year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.04. During the same period last year, the firm earned ($0.67) earnings per share. Sell-side analysts anticipate that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. The trade was a 27.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.25% of the stock is owned by insiders.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.